Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.

about

Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.

Item

http://www.wikidata.org/entity/Q36640582

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Triple-negative breast cancer ...... pression of topoisomerase IIα.

@ast

Triple-negative breast cancer ...... pression of topoisomerase IIα.

@en

type

Item

label

Triple-negative breast cancer ...... pression of topoisomerase IIα.

@ast

Triple-negative breast cancer ...... pression of topoisomerase IIα.

@en

prefLabel

Triple-negative breast cancer ...... pression of topoisomerase IIα.

@ast

Triple-negative breast cancer ...... pression of topoisomerase IIα.

@en

P1476

Triple-negative breast cancer ...... pression of topoisomerase IIα.

@en

P2093

Hiroko Nogi

http://www.w3.org/2001/XMLSchema#string

Hiroshi Takeyama

http://www.w3.org/2001/XMLSchema#string

Ken Uchida

http://www.w3.org/2001/XMLSchema#string

Kumiko Kato

http://www.w3.org/2001/XMLSchema#string

Makiko Kamio

http://www.w3.org/2001/XMLSchema#string

Masaaki Suzuki

http://www.w3.org/2001/XMLSchema#string

Tadashi Akiba

http://www.w3.org/2001/XMLSchema#string

Tadashi Kobayashi

http://www.w3.org/2001/XMLSchema#string

Toshiaki Morikawa

http://www.w3.org/2001/XMLSchema#string

Yasuo Toriumi

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and mechanism of DNA topoisomerase II

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Culprit and victim -- DNA topoisomerase II.

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

P304

383-389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2015.719

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287799682

http://www.w3.org/2001/XMLSchema#string

P698

26998288

http://www.w3.org/2001/XMLSchema#string

P932

4774539

http://www.w3.org/2001/XMLSchema#string